| Budget Amount *help |
¥136,760,000 (Direct Cost: ¥105,200,000、Indirect Cost: ¥31,560,000)
Fiscal Year 2022: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2021: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2020: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2019: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2018: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
|
|---|
| Outline of Final Research Achievements |
Ubiquitin modifications express their functions when they are recognized by specific decoder molecules (UBDs). In this study, we investigated the mechanism of functional expression of linear ubiquitin chains (M1 chains) by UBD recognition using chemical tools, and the possibility of disease therapy by inhibition of the function. We demonstrated a novel mechanism of inhibition of signal transduction by M1 chains and the possibility of cancer therapy by M1 chain inhibition. In addition, the contribution of LUBAC hyperfunction to the pathogenesis of systemic lupus erythematosus was also elucidated.
|
